DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This is a research study of a new experimental drug called darusentan. Darusentan is not
currently approved by the U.S. Food and Drug Administration (FDA) for use in the United
States, which means that a doctor cannot prescribe this drug. The purpose of this study is to
determine if darusentan is effective in reducing systolic blood pressure in subjects with
resistant systolic hypertension, despite treatment with full doses of three or more
antihypertensive drugs, including a diuretic.